IGI Logo

Key takeaways from management meet:

We attended Glenmark Pharmaceuticals' Investor Day 2026, where the management outlined its long-term vision of transforming GNP into a leading global innovation-driven pharmaceutical company.

It has devised a threepronged strategy:

(1) Scaling up branded businesses across India and Emerging Markets

(2) Strengthening differentiated respiratory and injectable franchises in developed markets

(3) Creating significant value through innovative oncology, dermatology and respiratory assets alongside the Ichnos Glenmark Innovation (IGI) platform. The management targets 13–15% revenue CAGR over the medium term and 21–22% structural EBITDA margin improvement in FY27E. It projects the margin expansion to 28% in FY28E, while maintaining superior return ratios and a net cash balance sheet. We maintain our ‘ADD’ rating on GNP with a TP of INR 2,590 on the basis of FY28E EPS

Long-term Vision:

The management aims to evolve Glenmark from a branded generics company into a global innovation-led pharmaceutical player with leadership positions in Respiratory, Dermatology and Oncology. By FY30, the revenue mix is expected to shift further towards branded and innovative products, with branded portfolio contributing over 70% of revenues. The 2026–2030 phase focuses on therapy area dominance across India and Emerging Markets, scaling up the US generics business through Respiratory and Injectable launches and advancing multispecific antibodies in IGI to clinical development, with partnerships of magnitude similar to the ISB 2001 AbbVie deal.

India & Emerging Markets:

GNP expects to continue to outperform the Indian Pharmaceutical Market and strengthening positions across Cardiac, Oncology, Respiratory and Dermatology therapies. Key strategic initiatives in India include scaling up the Oncology franchise anchored by Tevimbra and Brukinsa launches, adding 300–400 medical representatives every year and launching differentiated products in Chronic Respiratory and Cardiac therapies. It is also expecting to drive a turnaround in the Diabetes portfolio through the GLIPIQ launch and expanding its OTC/DTC verticals as an additional growth engine. Emerging Markets is anticipated to remain the fastest growing geography in the next five years, supported by expansion across Latin America, Russia/CIS, APAC and Africa.

Developed Markets:

In North America, GNP is focusing on respiratory and injectable platforms, targeting 2–3 respiratory launches in FY27E with 2–3 additional filings annually, while expanding injectable capacity at Monroe. Europe, driven by increasing contribution from branded respiratory products, such as Ryaltris, a growing dermatology portfolio, selective in-licensing and M&A opportunities is forecast to grow at high single or low double digits in FY27E.

Innovative Portfolio:

Ryaltris continues to be one of GNP’s most successful global assets with peak sales potential estimated at USD 250–300 Mn by FY32, with recent launches in China, Thailand and Brazil (FY27E) adding incremental revenue streams. Innovative oncology and specialty products including Tevimbra, Brukinsa, Aumolertinib (FY27E), QiNHAYO (FY28E) and Trastuzumab Rezetecan (FY29E) are expected to contribute meaningfully in the next 7–8 years, with the management estimating aggregate peak annual revenue potential of USD 700–800 Mn. The innovative portfolio is expected to contribute 30% of the branded generics mix by FY30.

IGI (Ichnos Glenmark Innovation):

IGI remains a key value creation platform with proprietary BEAT multispecific antibody technology and a growing oncology pipeline. The management targets one IND filing annually beginning FY27 and expects 3–4 multispecific antibodies to enter clinical development in the next few years. IGI with an average annual investment of USD 70 Mn, will remain self-sustaining through a diversified income model comprising development and regulatory milestone payments, new licensing partnerships, tiered royalties and a planned IPO.

View:

We remain positive on GNP’s long-term outlook, reinforced by a compelling multi-year earnings upgrade story driven by branded mix improvement, innovative product monetisation and IGI pipeline optionality. A structural shift is under way at GNP; transforming it from a diversified generics player towards a branded, speciality and innovation-driven pharmaceutical company. The combination of market-leading franchises in India and Emerging Markets, differentiated respiratory and injectable opportunities in developed markets, growing oncology commercialisation capabilities and significant optionality from the IGI platform provides multiple growth levers. Successful execution of the innovation strategy, coupled with continued improvement in product mix, should likely support a double-digit revenue growth with structural margin expansion.

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131